Neo Kuma Ventures invests in early stage psychedelic healthcare companies and digital therapeutics at the forefront of clinical research. Neo Kuma targets companies at the Pre-Seed to Series A stages of the financing process.
At present, their fund size is an estimated £20 million. Their extensive portfolio includes Atai Life Sciences, Beckley Psytech, Small Pharma and Awakn Life Sciences, to name a few.
Activities
Investor
Explore more company info with a Tree membership
📰 Weekly newsletter about the business of psychedelics
📈 Extended company information (analyst view, fundraising, revenue numbers)
🪄 Priority company page updates